Clinical trials of a vaccine direc...

Clinical trials of a vaccine directed at the three in the greatest degree globally important HIV subtypes have begun, according to a Nov 13 2002 of the present days release from the National Institutes of Health. The vaccine incorporates HIV genetic material from subtype A, B and C These subtype cause approximately 90% of HIV infections worldwide. This is the first multi-subtype HIV vaccine to chronicle human trials.

Scientists trust that this will lead to a vaccine that can obviate HIV infection. First, a multi-subtype vaccine must be cause to growed If it proves safe and effective, additional constitutings will be included in following trials in hopes of increasing an effective immune rejoinder The vaccine being used in the in every one's mouth trial is a DNA vaccine that incorporates parts of four HIV gene Three of these gene are taken from subtype B which predominates in North America and Europe The fourth gene taken from subtype A, B and C digests for a protein on the exterior coat of the virus that allows it to recognize and attach to human cells

The common vaccine is the first in which gene from the three subtype are combined. Subtype A and C are in the greatest degree common in Africa. A single vaccine that combines multiple component parts from different HIV subtypes could in theory, be effective in many places around the world. These gene fragments can stimulate an immune response; however, they cannot reconstitute into an infectious virus, meaning a individual cannot become infected with HIV from this vaccine.

Efforts to disentangle an effective HIV vaccine are complicated from the many subtypes and the disease's ability to frustrate immune system defenses through rapid mutation. Researchers are unsure whether a vaccine based in succession multiple subtypes will be more effective than single based on a single subtype nevertheless they hope clinical trials will provide an answer.

In the first phase of the trial, 50 healthy, HIV-negative offers will be vaccinated with either the ordeal vaccine or an inactive saline solution in increasing doses. Neither participants nor researchers will know to which assign places to participants are assigned. During the year-long trial, researchers will assess the vaccine's safety and note whether it induces any immune replication in the patients.

recent HIV Vaccine Holds Promise of Global Effectiveness (new release, Bethesda, Md: National Institutes of Health, Nov 13 2002) http:/www.nih.gov/news/pr/nov2002/ niaid-13.htm (accessed 19 Nov 2002)

COPYRIGHT 2003 Association of Operating play Nurses, Inc.

COPYRIGHT 2003 Gale Group